Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus

American Journal of Cardiology

Volumn 114, Issue 6, 2014, Pages 890-894

  Dominguez Rodriguez, Alberto ^a,b   Abreu Gonzalez, Pedro ^b,c   Avanzas, Pablo ^d  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b Instituto Universitario de Tecnologías Biomédicas Santa Cruz de Tenerife   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DIABETIC CARDIOMYOPATHY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREADMILL EXERCISE; VELOCITY;

EID: 84926195121     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.06.020     Document Type: Article

References (27)

1. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGFbeta superfamily. Proc Natl Acad Sci U S A 1997;94:11514-11519.
2. Dostálová I, Roubícek T, Bártlová M, Mráz M, Lacinová Z, Haluzíková D, Kaválková P, Matoulek M, Kasalicky M, Haluzík M. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol 2009;161:397-404.
3. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 2011;123:2101-2110.
4. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, Olofsson S, Venge P, Larsson A, Hulthe J, Elmgren A, Wollert KC. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009;30:2346-2353.
5. Schnabel RB, Schulz A, Messow CM, Lubos E, Wild PS, Zeller T, Sinning CR, Rupprecht HJ, Bickel C, Peetz D, Cambien F, Kempf T, Wollert KC, Benjamin EJ, Lackner KJ, Münzel TF, Tiret L, Vasan RS, Blankenberg S. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 2010;31:3024-3031.
6. Bell DSH. Diabetic cardiomyopathy. Diabetes Care 2003;26: 2949-2951.
7. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550.
8. Kan G, Visser CA, Lie KI, Durrer D. Early two-dimensional echocardiographic measurement of left ventricular ejection fraction in acute myocardial infarction. Eur Heart J 1984;5:210-217.
9. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, Lee MM, Park YB, Choi YS, Seo JD, Lee YW. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997;30:474-480.
10. Kral BG, Becker LC, Vaidya D, Yanek LR, Becker DM. Silent myocardial ischaemia and long-term coronary artery disease outcomes in apparently healthy people from families with early-onset ischaemic heart disease. Eur Heart J 2011;32:2766-2772.
11. Blumenthal RS, Becker DM, Moy TF, Coresh J, Wilder LB, Becker LC. Exercise thallium tomography predicts future clinically manifest coronary heart disease in a high-risk asymptomatic population. Circulation 1996;93:915-923.
12. Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with wellcontrolled type 2 diabetes mellitus. Am J Cardiol 2001;87:320-323.
13. Boyer JK, Thanigaraj S, Schechtman KB, Pérez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004;93:870-875.
14. Seferovic Mitrovic JP, Seferovic PM, Vujisic Tesic B, Petrovic M, Ristic AD, Lalic K, Jotic A, Tesic M, Giga V, Milic N, Singh S, Lalic NM. Predictors of diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes. Int J Cardiol 2012;156:219-221.
15. Vigili de Kreutzenberg S, Avogaro A. The limited clinical value of a specific diabetic cardiomyopathy. Nutr Metab Cardiovasc Dis 2013;23: 599-605.
16. Baessler A, Strack C, Rousseva E, Wagner F, Bruxmeier J, Schmiedel M, Riegger G, Lahmann C, Loew T, Schmitz G, Fischer M. Growthdifferentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur J Heart Fail 2012;14:1240-1248.
17. Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Lüers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 2010;12:1309-1316.
18. Rohatgi A, Patel P, Das SR, Ayers CR, Khera A, Martinez-Rumayor A, Berry JD, McGuire DK, de Lemos JA. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. Clin Chem 2012;58:172-182.
19. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. Prognostic value of growthdifferentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007;115:962-971.
20. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010;122:1387-1395.
21. Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KC. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2011;31:203-210.
22. Kiencke S, Handschin R, von Dahlen R, Muser J, Brunner-Larocca HP, Schumann J, Felix B, Berneis K, Rickenbacher P. Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur J Heart Fail 2010;12:951-957.
23. Romano S, Di Mauro M, Fratini S, Guarracini L, Guarracini F, Poccia G, Penco M. Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. Cardiovasc Diabetol 2010;9:89.
24. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/ reperfusion injury. Circ Res 2006;98:351-360.
25. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction. Am J Cardiol 2011;108: 955-958.
26. Albertini JP, Cohen R, Valensi P, Sachs RN, Charniot JC. B-type natriuretic peptide, a marker of asymptomatic left ventricular dysfunction in type 2 diabetic patients. Diabetes Metab 2008;34:355-362.
27. Kim JY, Lee EY, Jee JH, Lee BW, Chung JH, Jeun ES, Min YK, Lee MS, Kim KW, Lee MK. N-terminal pro-brain natriuretic peptide (NT-proBNP) in type 2 diabetes with left ventricular dysfunction. Diabetes Res Clin Pract 2007;77:S238-S242.